Blood-CNS Barrier Impairment in ALS patients versus an animal model by Svitlana Garbuzova-Davis & Paul R. Sanberg
REVIEW ARTICLE
published: 03 February 2014
doi: 10.3389/fncel.2014.00021
Blood–CNS barrier impairment in ALS patients versus an
animal model
Svitlana Garbuzova-Davis1,2 ,3* and Paul R. Sanberg1,2,3 ,4
1 Department of Neurosurgery and Brain Repair, Center of Excellence for Aging and Brain Repair, Morsani College of Medicine,
University of South Florida, Tampa, FL, USA
2 Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA
3 Department of Pathology and Cell Biology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA
4 Department of Psychiatry, Morsani College of Medicine, University of South Florida, Tampa, FL, USA
Edited by:
RicardoTapia, Universidad Nacional
Autónoma de México, Mexico
Reviewed by:
Hari S. Sharma, Uppsala University,
Sweden
Yang D. Teng, Brigham and Women’s
Hospital and Harvard Medical School,
USA
*Correspondence:
Svitlana Garbuzova-Davis, Department
of Neurosurgery and Brain Repair,
Center of Excellence for Aging and
Brain Repair, Morsani College of
Medicine, University of South Florida,
12901 Bruce B. Downs Boulevard,
Tampa, FL 33612, USA
e-mail: sgarbuzo@health.usf.edu
Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease with a com-
plicated and poorly understood pathogenesis. Recently, alterations in the blood–Central
Nervous System barrier (B-CNS-B) have been recognized as a key factor possibly aggra-
vating motor neuron damage. The majority of ﬁndings on ALS microvascular pathology
have been determined in mutant superoxide dismutase (SOD1) rodent models, identifying
barrier damage during disease development which might similarly occur in familial ALS
patients carrying the SOD1 mutation. However, our knowledge of B-CNS-B competence
in sporadic ALS (SALS) has been limited. We recently showed structural and functional
impairment in postmortem gray and white matter microvessels of medulla and spinal cord
tissue fromSALS patients, suggesting pervasive barrier damage. Although numerous signs
of barrier impairment (endothelial cell degeneration, capillary leakage, perivascular edema,
downregulation of tight junction proteins, and microhemorrhages) are indicated in both
mutant SOD1 animal models of ALS and SALS patients, other pathogenic barrier alterations
have as yet only been identiﬁed in SALS patients. Pericyte degeneration, perivascular
collagen IV expansion, and white matter capillary abnormalities in SALS patients are
signiﬁcant barrier related pathologies yet to be noted in ALS SOD1 animal models. In
the current review, these important differences in blood–CNS barrier damage between
ALS patients and animal models, which may signify altered barrier transport mechanisms,
are discussed. Understanding discrepancies in barrier condition between ALS patients and
animal models may be crucial for developing effective therapies.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease
affecting upper and lower motor neurons in the brain and
spinal cord, damage which leads to progressive muscle atro-
phy, paralysis and death typically within three to ﬁve years from
diagnosis (Rowland and Shneider, 2001). Most ALS cases are
sporadic amyotrophic lateral sclerosis(SALS) with only 5–10%
genetically linked familial amyotrophic lateral sclerosis (FALS);
20% of FALS cases show missense mutations in the Cu/Zn
superoxide dismutase (SOD1) gene (Rosen et al., 1993). Clin-
ical presentation and pathology of SALS and FALS, however,
are similar. Numerous hypotheses exist regarding ALS patho-
genesis (Alexianu et al., 2001; Cleveland and Rothstein, 2001;
Bruijn et al., 2004; Strong et al., 2005; Pasinelli and Brown,
2006; Van Den Bosch et al., 2006; Mitchell and Borasio, 2007;
Rothstein, 2009; Saleh et al., 2009; Hovden et al., 2013), but
the causes of the diffuse motor neuron degeneration are still
uncertain.
The blood–Central Nervous System barrier (B-CNS-B) is com-
posed of the blood–brain barrier (BBB), blood–spinal cord barrier
(BSCB), and blood–cerebrospinal ﬂuid barrier (BCSFB) and has a
crucial role in controlling CNS homeostasis by selective transport
of substances to and from the systemic compartment and block-
ing passive diffusion of harmful blood solutes (Bradbury, 1985;
Dermietzel and Krause, 1991; Pardridge, 1991, 1999; Nag, 2003;
Vorbrodt and Dobrogowska, 2003; Ballabh et al., 2004). This
control is possible due to the unique composition of the microvas-
culature – capillaries formed by endothelial cells (BBB and BSCB)
and epithelial cells of the choroids plexus (BCSFB). Exchange by
free diffusion is limited to molecules massing less than 450 Da;
more massive substances require speciﬁc transport mechanisms.
These mechanisms allow inﬂux of required substances and efﬂux
of cell waste (Begley andBrightman,2003; Begley, 2004; Pardridge,
2005). Endothelial cells and their tight/adherens junctions are the
primary components of the BBB and BSCB systems, while other
barrier elements (pericytes, astrocytes, perivascular macrophages,
and the basal lamina) also have essential roles in the tightly
integrated unit maintaining the CNS environment for proper
function of neuronal cells. Although major structural and func-
tional properties are shared between the BBB and BSCB, some
morphological and physiological differences have been noted in
the BSCB (Bartanusz et al., 2011). Glycogen microvessel deposits,
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increased capillary permeability for some tracers, and decreased
tight/adherence junction protein expressions were described for
the BSCB in comparison to the BBB. Therefore, dysfunctional or
structural impairment of any B-CNS-B component may lead to an
increasingly toxic CNS environment. Microvascular endothelial
dysfunction, in particular, might be implicated in the patho-
genesis of various neurodegenerative diseases (Grammas et al.,
2011).
Early studies in the 1980s reported altered BCSFB permeabil-
ity as indicated by abnormal serum proteins and complement in
the CSF of ALS patients (Leonardi et al., 1984; Annunziata and
Volpi, 1985). These observations were followed by detection of
blood-borne substances in the CNS tissue of ALS patients (Don-
nenfeld et al., 1984), suggesting BBB and BSCB leakage. Only
relatively recent research has focused on microvascular compe-
tence in the brain and spinal cord, indicating impairment of BBB
and BSCB integrity in animal models of ALS and in ALS patients.
Compelling evidence of this B-CNS-B damage has been demon-
strated at structural and functional levels in an animal model
of ALS at initial stage of disease and this damage was exacer-
bated with disease progression (Garbuzova-Davis et al., 2007a,b;
Zhong et al., 2008; Nicaise et al., 2009a,b; Miyazaki et al., 2011).
Importantly, BSCB breakdown was found in SOD1 mutant mice
and rats prior to motor neuron degeneration and neuroinﬂam-
mation (Zhong et al., 2008; Nicaise et al., 2009a; Miyazaki et al.,
2011). Evidence of BSCB impairment has also been observed
in postmortem tissue from ALS patients. Loss of endothelium
integrity, as shown by signiﬁcant reductions of tight junction
proteins and astrocyte end-feet dissociated from the endothe-
lium, was observed in spinal cords from ALS patients (Henkel
et al., 2009; Miyazaki et al., 2011). Recently, we showed struc-
tural and functional impairment in postmortem gray and white
matter microvessels of medulla and spinal cord tissue from
SALS patients, suggesting pervasiveness of the B-CNS-B dam-
age (Garbuzova-Davis et al., 2012). These results strengthen the
likelihood that barrier disruption contributes to disease pathogen-
esis (Garbuzova-Davis et al., 2008). However, B-CNS-B disruption
could also trigger, as well as aggravate, motor neuron degen-
eration in ALS. Vascular impairment has only recently been
recognized as a key factor in ALS, identifyingALS as a neurovascu-
lar disease (Garbuzova-Davis et al., 2011; Rodrigues et al., 2012).
Although numerous similarities in barrier damage have been iden-
tiﬁed in mutant SOD1 animal models of ALS and ALS patients,
some differences in the B-CNS-B alterations have been noted.
In the current review, these discrepancies in the BBB and BSCB
competence between ALS patients and animal models are dis-
cussed with an aim toward developing effective new therapies for
ALS.
BBB AND BSCB IMPAIRMENT IN TRANSGENIC RODENT
MODELS OF ALS
Only comparatively recent research has focused on investigations
of BBB and BSCB integrity in ALS. Initially, Garbuzova-Davis
et al. (2007a) demonstrated ultrastructural capillary alterations
in the brainstem and spinal cord (cervical and lumbar) in both
early and late stages of disease in G93A SOD1 mice. Electron
microscopy analysis showed highly vacuolated and degenerated
endothelial cells, mitochondrial degeneration within endothe-
lial cells, extensive perivascular edema, and swelling of astrocyte
end-feet adjacent to capillaries. Capillary rupture was also indi-
cated by the presence of erythrocytes in the extracellular space of
brainstem microvessels in early symptomatic G93A mice. These
ﬁndings were later conﬁrmed by a study from the same research
group (Garbuzova-Davis et al., 2007b), showing Evans blue leak-
age in spinal cord capillaries of G93A mice at 13 weeks of age,
indicating functional impairment of the BSCB in early stage dis-
ease. The study also demonstrated endothelial damage through
downregulation of the transporter protein Glut-1 and CD146
expressions, associated with decreased laminin, a component
of the basement membrane in capillaries. The alterations were
mainly detected in the ventral horns of the spinal cords, areas
most affected by ALS. Importantly, motor neurons demonstrated
intracellular edema and cytoplasmic vacuolization, in addition
to degenerated axons with myelin disruption near capillaries in
the brainstem and spinal cords of G93A mice at early disease
stage.
The study by Zhong et al. (2008) not only conﬁrmed these
observations on microvascular barrier damage in the spinal cord
of symptomatic G93Amice, but also showed that BSCBdisruption
precedes neuroinﬂammation and might initiate disease symp-
toms. Western blot analysis evidenced diminished levels of zonula
occludens-1 (ZO-1), occludin, and claudin-5 tight junction pro-
teins andGlut-1 prior to disease onset inALSmice. Although these
alterationswere observed,markers of endothelial activation (inter-
cellular adhesionmolecule-1, ICAM-1) and inﬂammation (mono-
cyte chemoattractant protein-1, MCP-1) and cycloxygenase-2
(COX-2) were not indicated. Also prior to motor neuron loss and
inﬂammatory changes, the investigators showed 10–15% reduc-
tions in total capillary length and 30 to 45% decreases in spinal
cord blood ﬂow of SOD1 transgenic mice. Additionally, microhe-
morrhages and hemosiderin deposits were found in spinal cord
parenchyma, demonstrating BSCB functional impairment and
disruption.
Miyazaki et al. (2011) also evaluated BSCB integrity in G93A
SOD1 mice and observed progressive downregulation of occludin
and platelet-endothelium cell adhesion molecule-1 (PECAM-1 or
CD31) and vascular collagen IV, associated with increased activity
of matrix metalloproteinase-9 (MMP-9), indicating endothe-
lial cell and basement membrane involvement in microvascular
pathological changes. All of these observations preceded motor
neuron death and were in agreement with Zhong et al. (2008).
However, the decline of occludin expression was moderate in the
spinal cord tissues from ALS mice from 10 to 15 weeks of age and
the expression of this protein signiﬁcantly decreased in late symp-
tomatic mice at 18 weeks of age. Surprisingly, the quantiﬁcation of
collagen IV in gray matter tissue evidenced protein up-regulation,
a ﬁnding in opposition to immunohistochemical observations in
the perivascular areas. These divergent results were ascribed to
increased glial production of collagen IV as a consequence of dis-
ease progression and neuroinﬂammation, possibly reﬂecting an
attempt by neural cells to compensate for endothelium disrup-
tion. In support of this suggestion, the authors showed higher
collagen IV expression in microglia of G93A mice at 18 weeks
of age vs. controls. Hence, it is still unclear whether glial cells,
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especially astrocytes, induce or prevent microvascular CNS barrier
damage.
Another study, based on the G93A SOD1 rat model of ALS,
demonstrated interesting results. Ultrastructural alterations of
the capillaries such as perivascular swollen astrocyte end-feet,
Evans blue leakage, reduced mRNA expression of ZO-1 and
occludin, and of agrin, a basement membrane component, were
observed in animals only at symptomatic stage (Nicaise et al.,
2009a). Conversely, IgG and hemosiderin deposits, other indi-
cators of capillary leakage, were detected in the brainstem and
lumbar spinal cord of pre-symptomatic ALS rats. Additionally,
the same group (Nicaise et al., 2009b) showed increased expres-
sion of aquaporin-4 (AQP4) mRNA and protein in the spinal
cord gray matter of end-stage SOD1 rats. Immunohistochem-
istry revealed increased AQP4 in areas surrounding vessels and
motoneuron perikaria. Electron microscopic analysis conﬁrmed
localization of this protein in associationwith perivascular swollen
astrocytic processes. The authors suggested that the aquaporin
channels may promote perivascular edema and AQR4 might be
a potential marker of barrier disruption in ALS (Nicaise et al.,
2010). Since elevatedAQP4 was also detected near motor neurons,
it is possible that dysfunctional astrocytes contribute to further
motor neuron degeneration. A more recent study by Bataveljic´
et al. (2012) conﬁrmed overexpression of AQP4 in the brain-
stem (facial and trigeminal nuclei) and motor cortex of G93A
SOD1 rats at end-stage of disease. Notably, increased AQP4
immunoreactivity was observed in astrocytic processes around
blood vessels in studied brain areas of ALS rats. In parallel, the
authors determined decreased expression of potassium channel
(Kir4.1) in the brainstem and cortex of rats by immunolabel-
ing and Western blot analyses. The authors concluded that the
functional changes in these channels could reduce astrocytes’ abil-
ity to properly maintain water and potassium CNS homeostasis,
not only affecting the BBB but also impeding motor neuron sur-
vival in ALS. Moreover, increased vascular permeability in the
brain was determined in symptomatic G93A SOD1 rats using
Gd-DTPA-enhanced MRI (Andjus et al., 2009). In addition to the
BBB leakage, the authors showed marked lateral ventricle dilata-
tion in ALS rats as “the most apparent feature of brain tissue
atrophy.”
Thus, the compromisedBBB andBSCB are evident in the SOD1
animalmodel of ALS. Endothelial cell degeneration, swollen astro-
cyte end-feet and dissociation from the endothelium, capillary
leakage, perivascular edema, downregulation of tight junction
proteins, microhemorrhages, and reduction of basement mem-
brane components are the main hallmarks of the B-CNS-B
impairment. This altered vascular barrier, normally preventing
entry of various blood-borne harmful substances into the CNS,
could contribute to motor neuron death. Although capillary bar-
rier damage in the CNS of both mouse and rat SOD1 models of
ALS has been demonstrated prior to motor neuron loss and neu-
roinﬂammation, the speciﬁc cause of B-CNS-B breakdown has
not yet been identiﬁed. It is possible that endothelial cells are more
susceptible to detrimental involvement of the misfolding mutant
SOD1 protein. However, the particular mechanism(s) responsible
for the endothelial cell alteration observed in ALS still needs to be
determined.
BBB AND BSCB IMPAIRMENT IN SPORADIC AND FAMILIAL
ALS PATIENTS
The transgenic rodent models expressing mutant SOD1 have
greatly contributed to the understanding of ALSpathogenesis. Rel-
atively new research on B-CNS-B competence in ALS has largely
used mutant SOD1 rodent models, but determination of bar-
rier integrity without involvement of the mutant SOD1 protein
is necessary to clarify the pathogenesis of sporadic human ALS
cases. ALS is a multifactorial disease with a complexity of underly-
ing intrinsic and extrinsic factors related to motor neuron death.
Someof these detrimental factorsmight be directly associatedwith
B-CNS-B impairment.
Although the B-CNS-B regulates cellular inﬁltration into the
CNS (Engelhardt, 2008), under inﬂammatory conditions, exten-
sive leukocyte migration into the CNS occurs following cytokine
releases from inﬂammatory/immune cells (de Vries et al., 1997;
Sagar et al., 2012; Sallusto et al., 2012). Leukocyte trafﬁcking
through the B-CNS-B is a multistep process mediated by adhe-
sion molecules, classiﬁed as immunoglobulins, integrins, cad-
herins, or selectins. These molecules are up-regulated on the
surfaces of the endothelial cells, allowing adhesion and migra-
tion of cells from the bloodstream to the CNS (Ley et al., 2007)
and are often accompanied by an increased inﬂux of serum
proteins. In example, Lindsberg et al. (2010) discussed the dele-
terious role of the mast cell, a potent inﬂammatory cell, in
cerebral ischemia. These cells locatedwithin the cerebralmicrovas-
culature secrete cytokines, histamine, heparin, and proteases
which can degrade the basement membrane and exacerbate bar-
rier damage, promoting edema, prolonged extravasation, and
microhemorrhage and attracting new inﬂammatory cells. The
paracellular pathway of cell migration through the capillary wall
is most common, but some authors hypothesize that penetra-
tion of immune cells into the CNS can also be accomplished
through the transcellular pathway with intact tight junctions
(Carman and Springer, 2008).
In the CNS tissue of ALS patients, inﬂammation and immune
cell activation have been detected and are associated with motor
neuron degeneration (Donnenfeld et al., 1984; Engelhardt and
Appel, 1990; Engelhardt et al., 1993, 1995; Henkel et al., 2004;
Boillée et al., 2006). Early studies found IgG and C3/C4 comple-
ment deposits in the spinal cord andmotor cortex tissues fromALS
patients (Donnenfeld et al., 1984). Engelhardt and Appel, (1990)
also detected active macrophages and IgG within the endoplas-
mic reticulum of motor neurons in ALS patients. Interestingly,
IgG from sera of ALS patients induced death of a motor neuron
cell line (VSC 4.1) in vitro (Engelhardt et al., 1995). These study
results suggest alteration of B-CNS-B permeability and thus recent
investigations have begun to focus on potential endothelial barrier
damage in ALS patients.
Henkel et al. (2009) demonstrated diminished mRNA expres-
sion of occludin and ZO-1 in human lumbar spinal cord tissue
fromboth sporadic and familial forms of ALS. Similarly, decreased
immunostaining for occludin was observed in a small cohort of
ALS patients (Miyazaki et al., 2011). These results agreed with the
experimental ﬁndings, conﬁrming loss of endothelial integrity,
and indicating BSCB disruption that might contribute to disease
pathogenesis.
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A study by Garbuzova-Davis et al. (2010) showed a signiﬁcant
reduction in the numbers of circulating endothelial cells in the
peripheral blood of ALS patients with moderate or severe disease.
Increased circulating endothelial cells is considered a marker for
endothelial damage (Blann et al., 2005) and has been noted in
several vascular diseases, including acute myocardial infarct and
acute ischemic stroke (Nadar et al., 2005; Chong et al., 2006).These
unexpected results inALSmaybe explained by a lack of endothelial
shedding, resulting in the attachment of new endothelial cells over
the damaged cells and thus a multilayer endothelium (Garbuzova-
Davis et al., 2010). Indeed, electron microscopy images of ALS
mouse tissue have revealed multiple layers of endothelial cells
in the brain and spinal cord capillaries (Garbuzova-Davis et al.,
2007a). Also, a reduction of circulating endothelial cells in periph-
eral blood of ALS patients with disease progression could be due
to impaired re-endothelialization. The structural and functional
integrity of the vascular network, normally maintained by contin-
uous renewal of the endothelial cell layer with a low replication
rate of 0.1% per day (Hunting et al., 2005), might be weakened
in ALS. It is possible that insufﬁcient production of endothelial
progenitor cells by the bone marrow might be an issue. Recent
reports demonstrated the functional deﬁciency of bone mar-
row mesenchymal stromal cell in ALS patients by reductions in
pluripotency and secretion of various trophic factors (Koh et al.,
2012) as well as by abnormal productions of MMPs and tissue
inhibitors of metalloproteinases (TIMPs; Bossolasco et al., 2010).
In our recent study (Garbuzova-Davis et al., 2012), we exam-
ined structural and functional integrities of capillaries in the gray
and white matter of the brainstem (medulla) and spinal cord
(cervical and lumbar) in postmortem tissue from SALS patients.
Study results showed capillary ultrastructural abnormalities in
CNS tissues from SALS patients, similar to results from our
animal studies (Garbuzova-Davis et al., 2007a). Mainly, severe
intra- and extracellular edema, endothelial cell impairment as
characterized by swelling and cytoplasmic vacuolization, pericyte
degeneration, and degeneration of astrocyte end-feet processes
surrounding capillaries were determined by electron microscopic
analysis of the medulla and spinal cords. Also, separation of the
endothelial cells from the basement membrane, allowing plasma
to contact the basal lamina, was a signiﬁcant capillary alter-
ation noted in brain and spinal cord tissues of SALS patients.
Observed capillary endothelium damage led to vascular leakage
in the brain and spinal cord as determined by immunostaining
for endogenous IgG, conﬁrming previous study results on an ani-
mal model of ALS (Garbuzova-Davis et al., 2007b; Nicaise et al.,
2009a). Microvascular leakage was also determined in CNS tissues
from SALS patients by perivascular ﬁbrin deposits in our electron
microscopy images and was recently conﬁrmed (Winkler et al.,
2013). Winkler et al. (2013) additionally demonstrated parenchy-
mal accumulationof the plasma-derivedproteins trombin and IgG
as well as erythrocyte-derived hemoglobin and iron-containing
hemosiderin in the cervical gray matter from both SALS and FALS
patients via immunostaining. The authors noted that these abnor-
mal deposits in the postmortem tissues were detected only in
tissues from ALS patients, but not from controls, and there were
unusually widespread pathological depositions at a signiﬁcant
distance from capillaries. In our study (Garbuzova-Davis et al.,
2012), ﬁbrin ﬁlament deposits and IgG leakage, determined by
electron microscopic and immunostaining analysis respectively,
were predominantly limited to within the capillary basement
membrane or were in close proximity to capillaries. Moreover,
erythrocyte extravasation was not determined perivascularly or at
neuropil locations in our numerous electron microscope images
at different magniﬁcations of the medulla, cervical and lum-
bar spinal cords from ALS patients. Microhemorrhages within
CNS tissues in ALS are possible, even though not supported by
MRI evaluations of microbleeds in the brain of ALS patients
(Verstraete et al., 2010), so the presence of erythrocytes in CNS
parenchyma observed by Winkler et al. (2013) needs further con-
ﬁrmation. Erythrocytes are normally restricted from entry into
the CNS and these cells typically extravasate into CNS tissue due
to capillary rupture as shown in multiple sclerosis (Adams, 1988),
post-traumatic epilepsy (Willmore and Triggs, 1984), and cerebral
ischemia (Simard et al., 2007). However, capillary rupture was not
evident morphologically in the brain or spinal cords from ALS
patients, even by electron microscopy imaging.
Importantly, complementary approaches have identiﬁed peri-
cyte degeneration by electron microscopy (Garbuzova-Davis et al.,
2012) and shown reduction in pericyte numbers via immunostain-
ing (Winkler et al., 2013) in capillaries of ALS patients, deﬁciencies
which might severely compromise the B-CNS-B. Hence, the
cause(s) of pericyte deterioration in human ALS tissues should
be determined.
Additionally, analysis of tight junction protein expressions
in our study (Garbuzova-Davis et al., 2012) using Western
immunoblot showed signiﬁcant decreases of primarily ZO-1
expression in gray and white matter in all examined SALS tissues,
similarly to previous studies (Henkel et al., 2009; Miyazaki et al.,
2011). For occludin and claudin-5, diminishedprotein expressions
were mostly found in ALS medulla and cervical spinal cord.
Moreover, our new ﬁndings (Garbuzova-Davis et al., 2012)
showed extensive vascular basement membrane collagen IV accu-
mulation, 2–2.5 times higher than controls, in the majority of
brain and spinal cord vessels from SALS patients. Also, colla-
gen ﬁber calciﬁcations were determined in some CNS capillar-
ies. Although similar results were noted in Alzheimer’s patients
(Claudio, 1996), some previous reports conﬂict with our study
results. Decreased perivascular collagen IV was noted in post-
mortem ALS spinal cord tissue (Ono et al., 1998; Miyazaki et al.,
2011). This discrepancy needs clariﬁcation.
Finally, our study results showed a signiﬁcant increase of
microvascular density in gray matter of the lumbar spinal cord
from SALS patients vs. controls (Garbuzova-Davis et al., 2012)
suggesting that neovascularization occurred to compensate for
vascular insufﬁciency due to dysfunctional capillaries. Currently,
we are investigating possible new vessel formation in both an ALS
mouse model and ALS patients. Supporting the likelihood of ALS
neovascularization, Biron et al. (2011) similarly (to our results)
demonstrated increased microvascular density in brains from
Alzheimer’s patients, suggesting a relationship between hyper-
vascularity, neoangiogenesis and BBB disruption. Also, ongoing
angiogenesis resulted in increased vascular density in postmortem
brain tissues, mainly in the hippocampus, in Alzheimer’s patients
(Desai et al., 2009). Recently, Desai Bradaric et al. (2012) showed
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the presence of newly created vessels in postmortem brain tis-
sues such as the substantia nigra pars compacta, locus ceruleus,
and putamen from subjects with Parkinson’s disease and pro-
gressive supranuclear palsy. The authors suggest that these new
angiogenic vessels could contribute to disease inﬂammatory pro-
cesses by failing to restrict extravasation of immune cells and
inﬂammatory or toxic factors from the peripheral circulation
to the CNS due to the new vessels having incompletely devel-
oped BBB properties. This possibility might also be an issue for
ALS.
Thus, there is compelling evidence of BBB and BSCB impair-
ment in areas of motor neuron degeneration in ALS patients.
Importantly, microvascular alterations seen in both gray and
white matter of medulla, cervical, and lumbar spinal cord from
SALS patients indicate pervasive B-CNS-B damage that might
contribute to disease pathogenesis.
SIMILARITIES AND DIFFERENCES IN THE B-CNS-B
IMPAIRMENT BETWEEN ALS PATIENTS AND ANIMAL
MODELS OF ALS
Convincing ﬁndings indicate B-CNS-B alterations in both ALS
patients and the SOD1 animal model of ALS and suggest these
alterations as a possible factor aggravating motor neuron damage.
Numerous signs of barrier damage, such as endothelial cell degen-
eration, capillary leakage, perivascular edema, downregulation of
tight junction proteins, and microhemorrhages are common in
both mutant SOD1 animal models of disease and ALS patients. To
date, other pathogenic features linked to barrier alterations have so
far only been identiﬁed in ALS patients. Mainly, pericyte degener-
ation, perivascular basement membrane collagen IV expansion,
and white matter capillary abnormalities in SALS patients are
signiﬁcant barrier related pathologies yet to be noted in ALS
SOD1 animal models. In Table 1, current evidence of B-CNS-B
impairment in ALS is provided from animal and human studies.
Severe capillary pericyte damage (Garbuzova-Davis et al., 2012;
Winkler et al., 2013) is an important ﬁnding inALS patients. At the
ultrastructural level, complete pericyte degeneration or cell frag-
mentation in the adjacent extracellular space was determined in
numbers of gray and white matter microvessels in the medulla and
cervical/lumbar spinal cord of SALS patients (Garbuzova-Davis
et al., 2012). Pericytes play essential roles in maintaining B-CNS-B
integrity by regulating capillary permeability, blood ﬂow, vascu-
lar tone, and angiogenesis (Hirschi and D’Amore, 1996; Kutcher
and Herman, 2009; Armulik et al., 2010; Winkler et al., 2011,
2012; Sá-Pereira et al., 2012). These functions are associated with
the cells’ anatomical location, in close proximity to endothelial
cells and sharing a common basement membrane. Pericytes are
also involved in modulation of immunological response by their
phagocytic function (Balabanov and Dore-Duffy, 1998; Dalkara
et al., 2011). For example, amyloid deposits within degenerat-
ing pericytes were detected in the brains of Alzheimer’s patients
(Dalkara et al., 2011). The authors discussed the role of per-
icyte dysfunction in cerebral hypoperfusion and suggest that
“microvascular dysfunction due to pericyte degeneration initiates
secondary neurodegenerative changes” (Dalkara et al., 2011). In
ALS, Rule et al. (2010) reported reduced capillary blood ﬂow in
Table 1 | Evidence of blood–CNS barrier impairment in ALS patients and SOD1 animal models of ALS.
References
Description of evidence Animal model of ALS HumanALS
Endothelial cell degeneration or damage Garbuzova-Davis et al. (2007a), Nicaise et al.
(2009a), Miyazaki et al. (2011)
Garbuzova-Davis et al. (2012)
Capillary leakage Garbuzova-Davis et al. (2007b), Nicaise et al.
(2009a), Andjus et al. (2009)
Garbuzova-Davis et al. (2012), Winkler et al. (2013)
Pericyte degeneration or damage Garbuzova-Davis et al. (2012), Winkler et al. (2013)
Perivascular edema Garbuzova-Davis et al. (2007a) Garbuzova-Davis et al. (2012)
Astrocyte end-feet capillary damage and
dissociation
Garbuzova-Davis et al. (2007a,b), Nicaise et al.
(2009a), Miyazaki et al. (2011), Bataveljic´ et al.
(2012)
Miyazaki et al. (2011), Garbuzova-Davis et al. (2012)
Altered basement membrane components Garbuzova-Davis et al. (2007b), Nicaise et al.
(2009a), Miyazaki et al. (2011)
Ono et al. (1998), Miyazaki et al. (2011),
Garbuzova-Davis et al. (2012)
Microhemorrhages or
perivascular hemosiderin
Garbuzova-Davis et al. (2007a), Zhong et al. (2008),
Nicaise et al. (2009a)
Verstraete et al. (2010) (unsupporting), Winkler
et al. (2013)
Altered blood ﬂow or capillary lengths and
diameters
Zhong et al. (2008), Miyazaki et al. (2011) Rule et al. (2010)
Downregulation of junctional complex proteins Zhong et al. (2008), Nicaise et al. (2009a), Miyazaki
et al. (2011)
Henkel et al. (2009), Miyazaki et al. (2011),
Garbuzova-Davis et al. (2012)
Altered endothelial transporter protein
expression
Garbuzova-Davis et al. (2007b), Zhong et al. (2008),
Milane et al. (2010), Jablonski et al. (2012)
Jablonski et al. (2012)
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brains of patients correlating with disease severity, a reduction
likely associated with pericyte impairment. A similar decrease in
blood ﬂow was determined in the spinal cord of G93A SOD1 mice
preceding inﬂammation and motor neuron injury (Zhong et al.,
2008). However, there were no obvious abnormalities detected
in pericyte morphology in the brainstem or spinal cord capillar-
ies via electron microscope even in late symptomatic G93A mice
(Garbuzova-Davis et al., 2007a). This discrepancy between animal
data and results from ALS patients should be investigated.
Another difference between human and animal studies in ALS
is vascular basement membrane collagen IV abnormalities. As
we noted above, our recent study (Garbuzova-Davis et al., 2012)
showed extensive basement membrane collagen IV accumulation
and even collagen ﬁber calciﬁcations in numerous capillaries in
gray and white matter brain and spinal cords from SALS patients.
However, opposing reports demonstrated decreased perivascular
collagen IV in postmortem ALS spinal cord tissue (Ono et al.,
1998; Miyazaki et al., 2011). In a study by Miyazaki et al. (2011),
reduction of immunoexpression for collagen IV was observed in
the anterior horns of the spinal cord from ALS patients as well
as in G93A mice during disease progression and was accompa-
nied by MMP-9 up-regulation. The authors conclude that this
vascular damage is common to humans and this ALS animal
model. However, the observed collagen IV reduction might be
due to the diminished capillary density described in the same
study. In addition, the authors provided conﬂicting data with
double immunoﬂuorescence staining for collagen IV and Iba-1
(microglial marker) in the spinal anterior horn of G93A mice at
18 weeks of age showing higher collagen IV expression vs. con-
trols along with the appearance of collagen IV-positive microglia.
Microglial cells are resident cells in the CNS with macrophagic
properties upon their activation and likely overexpression of col-
lagen IV by microglia indicates uptake of this protein. Supportive
evidence of the ability of microglia to express collagen IV was
not provided (Miyazaki et al., 2011). Also, it is unclear if this col-
lagen IV immunostaining was also associated with capillaries or
astrocytes. Double immunostaining for collagen IV and astrocytes
might be a reasonable conﬁrming procedure. It has been shown
that reactive astrocytes expressed type IV collagen after spinal
cord injury in promoting glial scar formation (Liesi and Kauppila,
2002). In the same study, the authors reported that IL-1 beta and
TGF beta-1 cytokines induced collagen IV expression in astrocytes
in vitro. Since reactive astrogliosis and microglia activation are
major contributors to inﬂammatory processes in ALS by secretion
of various pro-inﬂammatory cytokines, particularly TNF-alpha
and TGF beta-1 (Schiffer et al., 1996; Hall et al., 1998; McGeer and
McGeer, 1998; Elliott, 2001; McGeer and McGeer, 2002; Consilvio
et al., 2004; Henkel et al., 2004; Xie et al., 2004; Vargas and John-
son, 2010; Appel et al., 2011; Haidet-Phillips et al., 2011; Sica, 2012;
Evans et al., 2013; Phatnani et al., 2013) it is possible that reactive
astrocytes not only affect motor neurons but also promote a col-
lagenous vascular basement membrane. Moreover, inﬂammation
may initiate barrier damage by impairing endothelial cell function.
Mantovani et al. (1992) showed that the inﬂammatory environ-
ment in ALS affected endothelial cell gene expression, altering
cell function. An additional discrepancy between our and the
above mentioned studies regarding basement membrane collagen
deposition was discussed in detail (Garbuzova-Davis et al., 2012)
and primarily focused on the potential imbalance between MMPs
and TIMPs due to defective regulation of the MMP pathway by
damaged endothelial cells. Also, since downregulation of other
basement membrane components such as laminin (Garbuzova-
Davis et al., 2007b) and argin (Nicaise et al., 2009a) has been shown
in symptomatic G93A mice but not yet conﬁrmed in ALS patients,
it is possible that buildup of perivascular collagen IV occurs as a
compensatory mechanism for maintenance of vascular integrity.
We strongly believe that abnormal perivascular collagen accu-
mulation in SALS patients takes place over a long period of
time. Our notion is partially supported by Ono et al. (1998)
who showed widely separated and fragmented collagen bundles
in the interstitial tissue surrounding capillaries in the poste-
rior half of lateral funiculus and anterior horn of cervical
spinal cord from ALS patients by ultrastructural analysis. Yet
total collagen content determined for each of these spinal cord
regions was lower in ALS patients than in controls with or
without neurological diseases. Although these data are inter-
esting, the existence of basement collagen abnormalities needs
clariﬁcation.
Thus, the complexity of the B-CNS-B alterations in ALS is
evident. Commonalities in barrier pathologies between humans
and an animal model of ALS are essential for understanding
involvement of the B-CNS-B in disease pathogenesis. However,
the disparities in barrier competence in humans with ALS vs. ani-
malmodel shouldbe considered. Despite a growing research effort,
more studies are needed to reveal speciﬁc mechanisms of barrier
breakdown in ALS. The question still remains: is barrier damage
an initial disease factor or a secondary element in human ALS?
CONCLUSION
ALS has been, and remains, a challenge for developing therapeu-
tics. More than 30 drug compounds have already been tested
in ALS clinical trials yet the only modestly effective treatment
is riluzole (Aggarwal and Cudkowicz, 2008). Some tested sub-
stances failed to prove effective and even showed harmful effects
in Phase III clinical trials: IGF-1 (insulin-like growth factor type 1;
Sorenson et al., 2008), minocycline (Gordon et al., 2007), creatine
(Groeneveld et al., 2003), and topiramate (Cudkowicz et al., 2003).
These disappointing results might reﬂect defective transport
systems in damaged BBB and BSCB in ALS. Degeneration of
endothelial and pericyte cells, compromising vascular barrier
integrity in the brain and spinal cord in ALS patients, could be
the main obstacles for effective drug delivery to the CNS. Also,
it is hard to imagine proper transport of pharmaco-therapeutics
across an extensively expanded vascular collagenous basement
membrane. Such abnormal buildup of basementmembrane colla-
gen seems likely to alter barrier inﬂux and efﬂux transport systems
and, as result, motor neurons might suffer both from reduced
nutritional deliveries and increasedmetabolite levels. Additionally,
increases of P-glycoprotein (P-gp) along with the breast cancer
resistance protein (BCRP) were determined in brain and spinal
cord microvessels in both SOD1 animal models and ALS patients
(Milane et al., 2010; Jablonski et al., 2012). Jablonski et al. (2012)
conclude that the impairment of these P-gp and BCRP efﬂux
transporters might induce pharmaco-resistance in ALS.
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Numerous comprehensive reviews discuss therapeutic strate-
gies of transport drugs across the blood–CNS barrier (Abbott
and Romero, 1996; Pardridge, 2002; Misra et al., 2003; McCarty,
2005; Patel et al., 2009; Pathan et al., 2009; Gabathuler, 2010)
including chemical (i.g., lipid-mediated transport), biological (i.g.,
speciﬁc transporters for pharmaceuticals), or particular drug car-
rier systems. Also, various drug delivery systems (e.g., liposomes,
nanoparticles, or microspheres) and routes (e.g., intranasal, intra-
ventricular, or intrathecal) have been proposed. However, all of
these various strategies for effective drug delivery to the CNS rely
on a normally functioning BBB/BSCB. In ALS, deliveries of ther-
apeutic drugs are likely to be complicated by the pervasiveness of
the B-CNS-B damage.
In conclusion, the blood–CNSbarrier should be considered as a
primary therapeutic target prior to development of any treatment
approach for ALS.
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